Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro

Journal of Bone and Mineral Research

Volumn 23, Issue 6, 2008, Pages 939-948

  Wang, Hua ^a,b   Yoshiko, Yuji ^a   Yamamoto, Ryoko ^a   Minamizaki, Tomoko ^a   Kozai, Katsuyuki ^a   Tanne, Kazuo ^a   Aubin, Jane E ^c   Maeda, Norihiko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bone formation; Fibroblast growth factor 23; Fibroblast growth factor receptor; Rat calvaria osteoblasts

Indexed keywords

3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; CALCEIN; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1;

ANIMAL TISSUE; ARTICLE; BONE MATRIX; CALVARIA; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; FETUS; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MINERALIZATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOMALACIA; PHOSPHATURIA; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; RICKETS;

ANIMALS; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELLS, CULTURED; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HUMANS; OSTEOBLASTS; RATS; RATS, WISTAR; RECEPTORS, FIBROBLAST GROWTH FACTOR; SKULL; TISSUE CULTURE TECHNIQUES;

EID: 44449118964     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080220     Document Type: Article

References (46)

1. Consortium ADHR 2000 Autosomal dominant hypophosphatasemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348.
2. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2002 Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179-3182.
3. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505.
4. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663.
5. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-568.
6. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421-432.
7. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the α(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087-3094.
8. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2004 FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314:409-414.
9. Bai X, Miao D, Li J, Goltzman D, Karaplis AC 2004 Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145:5269-5279.
10. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692.
11. Mirams M, Robinson BG, Mason RS, Nelson AE 2004 Bone as a source of FGF23: Regulation by phosphate? Bone 35:1192-1199.
12. Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne K, Aubin JE, Maeda N 2007 Mineralized tissue cells are a principal source of FGF23. Bone 40:1565-1573.
13. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960.
14. Quarles LD 2003 Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest 112:642-646.
15. Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto K, Fukushima N 2003 Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate cotransport activity and 1α, 25-dihydroxyvitamin D3 production. J Biol Chem 278:2206-2211.
16. Segawa H, Kawakami E, Kaneko I, Kuwahata M, Ito M, Kusano K, Saito H, Fukushima N, Miyamoto K 2003 Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter. Pflugers Arch 446:585-592.
17. Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-O M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J 2007 The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003-4008.
18. Givol D, Yayon A 1992 Complexity of FGF receptors: Genetic basis for structural diversity and functional specificity. FASEB J 6:3362-3369.
19. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M 1996 Receptor specificity of the fibroblast growth factor family. J Biol Chem 271:15292-15297.
20. Ornitz DM, Marie PJ 2002 FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16:1446-1465.
21. Jackson RA, Nurcombe V, Cool SM 2006 Coordinated fibroblast growth factor and heparan sulfate regulation of osteogenesis. Gene 379:79-91.
22. Yamashita T, Konishi M, Miyake A, Inui K, Itoh N 2002 Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277:28265-28270.
23. Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, White KE 2005 Analysis of the biochemical mechanisms for the endocrine actions of FGF23. Endocrinology 146:4647-4656.
24. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M 2006 Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120-6123.
25. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T 2006 Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774.
26. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M 2005 Suppression of aging in mice by the hormone Klotho. Science 309:1829-1833.
27. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T, Nabeshima Y 2004 Secreted Klotho protein in sera and CSF: Implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 565:143-147.
28. Yoshiko Y, Maeda N, Aubin JE 2003 Stanniocalcin 1 stimulates osteoblast differentiation in rat calvaria cell cultures. Endocrinology 144:4134-4143.
29. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J 1997 Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276:955-960.
30. Debiais F, Hott M, Graulet AM, Marie PJ 1998 The effects of fibroblast growth factor-2 on human neonatal calvaria osteoblastic cells are differentiation stage specific. J Bone Miner Res 13:645-654.
31. Kim HJ, Rice DP, Kettunen PJ, Thesleff I 1998 FGF-, BMP-and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development. Development 125:1241-1251.
32. Iseki S, Wilkie AO, Morriss-Kay GM 1999 Fgfr1 and Fgfr2 have distinct differentiation- and proliferation-related roles in the developing mouse skull vault. Development 126:5611-5620.
33. Rice DP, Aberg T, Chan Y, Tang Z, Kettunen PJ, Pakarinen L, Maxson RE, Thesleff 12000 Integration of FGF and TWIST in calvarial bone and suture development. Development 127:1845-1855.
34. Ohbayashi N, Shibayama M, Kurotaki Y, Imanishi M, Fujimori T, Itoh N, Takada S 2002 FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev 16:870-879.
35. Shimoaka T, Ogasawara T, Yonamine A, Chikazu D, Kawano H, Nakamura K, Itoh N, Kawaguchi H 2002 Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10. J Biol Chem 277:7493-7500.
36. Ignelzi MA Jr, Wang W, Young AT 2003 Fibroblast growth factors lead to increased Msx2 expression and fusion in calvarial sutures. J Bone Miner Res 18:751-759.
37. Fakhry A, Ratisoontorn C, Vedhachalam C, Salhab I, Koyama E, Leboy P, Pacifici M, Kirschner RE, Nah HD 2005 Effects of FGF-2/-9 in calvarial bone cell cultures: Differentiation stage-dependent mitogenic effect, inverse regulation of BMP-2 and noggin, and enhancement of osteogenic potential. Bone 36:254-266.
38. Sobue T, Naganawa T, Xiao L, Okada Y, Tanaka Y, Ito M, Okimoto N, Nakamura T, Coffin JD, Hurley MM 2005 Overexpression of fibroblast growth factor-2 causes defective bone mineralization and osteopenia in transgenic mice. J Cell Biochem 95:83-94.
39. Valta MP, Hentunen T, Qu Q, Valve EM, Harjula A, Seppanen JA, Vaananen HK, Harkonen PL 2006 Regulation of osteoblast differentiation: A novel function for fibroblast growth factor 8. Endocrinology 147:2171-2182.
40. Yoshiko Y, Candeliere GA, Maeda N, Aubin JE 2007 Osteoblast autonomous Pi regulation via Pit1 plays a role in bone mineralization. Mol Cell Biol 27:4465-4474.
41. Hoang QQ, Sicheri F, Howard AJ, Yang DS 2003 Bone recognition mechanism of porcine osteocalcin from crystal structure. Nature 425:977-980.
42. Wennberg C, Hessle L, Lundberg P, Mauro S, Narisawa S, Lerner UH, Millán JL 2000 Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice. J Bone Miner Res 15:1879-1888.
43. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa A, Nagai R, Nabeshima Y 1997 Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51.
44. Razzaque MS, Sitara D, Taguchi T, St-Arnaud R, Lanske B 2006 Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 20:720-722.
45. Kawaguchi H, Manabe N, Miyaura C, Chikuda H, Nakamura K, Kuro-o M 1999 Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J Clin Invest 104:229-237.
46. Kawaguchi H, Manabe N, Chikuda H, Nakamura K, Kuro-o M 2000 Cellular and molecular mechanism of low-turnover osteopenia in the klotho-deficient mouse. Cell Mol Life Sci 57:731-737.